13.08.2010
- Hard to Copy - Market data shows that sales of biotech products are worth billions of dollars worldwide - just the sort of prospect that normally brings generic manufacturers...
09.08.2010
- Paris-based drugmaker Sanofi-Aventis may need weeks of haggling to get a deal on buying U.S. biotech firm Genzyme as the two appear wide apart over price. Neither party has...
04.08.2010
- Sanofi-Aventis has grabbed the headlines with its $18.4 billion bid for Genzyme, but the French drugmaker may be wiser to stick with smaller, bolt-on acquisitions. Sanofi is trying...
04.08.2010
- Sanofi-Aventis investors have urged the drugmaker not to pay more than about $19 billion to land Genzyme, some $10 a share below the price wanted by the U.S. biotech group. Two...
03.08.2010
- Sanofi-Aventis chief executive Chris Viehbacher should aim to land U.S. biotech group Genzyme for around$19 billion to keep his investors on side, according to institutional...
02.08.2010
- Chances are, every big pharmaceutical company is running the numbers and weighing the pros and cons of acquiring Genzyme. French drugmaker Sanofi-Aventis is poised to make a bid...
30.07.2010
- Sanofi-Aventis Chief Executive Chris Viehbacher delivered forecast-beating second quarter results onThursday as he prepared to bid $18.7 billion for U.S biotech group Genzyme...
29.07.2010
- Sanofi-Aventis beat second-quarter earnings expectations as it beefed up sales and tightened its R&D spending, but the French drugmaker gave no hint in its results statement of any...
29.07.2010
- The European Commission on Wednesday approved six genetically modified (GM) maize varieties for import to the bloc in a sign of its desire to speed up European Union decisions on...
27.07.2010
- Biotechnology company Genzyme is weighing an informal takeover approach from France's Sanofi-Aventis, but has no current interest in selling the company, a source familiar with the...
